Cargando…
Real-World Clinical Characterisation of Polycythaemia Vera Patients from a Prospective Registry in Portugal: Is Resistance to Hydroxyurea a Reality?
Patients with polycythaemia vera (PV) are at increased risk of thrombosis and haemorrhages. Although hydroxyurea (HU) has been the frontline therapy for patients at high risk of vascular complications, about 25% of patients develop resistance/intolerance to this therapy. The aim of this non-interven...
Autores principales: | Sarmento, Maria, Duarte, Marta, Ponte, Sandra, Sanchez, Juan, Roriz, Diana, Fernandes, Laura, Silva, Maria José Monteiro, Pacheco, Judite, Ferreira, Gisela, Freitas, Jorge, Costa, Inês, Brás, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10530755/ https://www.ncbi.nlm.nih.gov/pubmed/37754671 http://dx.doi.org/10.3390/hematolrep15030056 |
Ejemplares similares
-
Koilonychia and Polycythæmia Vera
por: Glazebrook, A. J.
Publicado: (1944) -
Unusual Neurological Symptoms in Polycythæmia Rubra Vera
por: Grunberg, A., et al.
Publicado: (1950) -
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study
por: Palandri, Francesca, et al.
Publicado: (2023) -
Masked polycythaemia vera is genetically intermediate between JAK2V617F mutated essential thrombocythaemia and overt polycythaemia vera
por: Tiong, I S, et al.
Publicado: (2016) -
The treatment of polycythaemia vera: an update in the JAK2 era
por: Finazzi, G., et al.
Publicado: (2007)